These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10947490)

  • 1. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
    Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 5. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
    Gabelli C
    Curr Med Res Opin; 2003; 19(2):69-82. PubMed ID: 12740150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
    Baladi JF; Bailey PA; Black S; Bouchard RW; Farcnik KD; Gauthier S; Kertesz A; Mohr E; Robillard A
    Clin Ther; 2000 Dec; 22(12):1549-61. PubMed ID: 11192146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
    Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
    Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
    Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
    Finkel SI
    Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of rivastigmine: a reversible cholinesterase inhibitor.
    Williams BR; Nazarians A; Gill MA
    Clin Ther; 2003 Jun; 25(6):1634-53. PubMed ID: 12860489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
    Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y
    Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.